CoQ10 (Ubiquinol/Ubiquinone) — Expert Claims
Extracted from publicly available podcast transcripts and videos. Each claim is attributed and sourced.
Claims are extracted using AI (Claude) from publicly available transcripts and manually reviewed. Extraction confidence (high / medium / low) indicates accuracy of capture. Each claim is compared against PubMed research.
44 expert mentions
"The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis."
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
"The patients who seem to benefit most are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis."
The patients who seem to benefit most from CoQ10 are those with documented mitochondrial dysfunction, those on statins, and older individuals with naturally declining CoQ10 synthesis.
The expert's claim identifies three populations (mitochondrial dysfunction patients, statin users, older individuals) as primary CoQ10 beneficiaries. The provided literature includes a review on disorders of human CoQ10 metabolism (PMID: 32933108) and clinical applications of CoQ10 (PMID: 24389208) that are conceptually relevant to mitochondrial dysfunction and aging-related decline, and a review comparing ubiquinone and ubiquinol for cardiovascular outcomes (PMID: 37971634) tangentially relevant to statin users. However, none of the retrieved studies provide key findings, populations, or limitations data, making it impossible to directly verify the claim's specifics against study-level evidence. The claim is biologically plausible and consistent with the general focus of the identified reviews, but direct empirical support cannot be confirmed from the data as presented.
"My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat."
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
"My general recommendation for patients over 60 who are on statins: ubiquinol 100 to 200 milligrams with a meal containing fat."
Attia's general recommendation for patients over 60 who are on statins is ubiquinol 100 to 200 milligrams taken with a meal containing fat.
The provided research abstracts lack extractable key findings, populations, and limitations, making direct comparison impossible. While several relevant CoQ10 reviews are listed (PMIDs 33325173, 24389208, 37971634, 34129891), none contain usable data to evaluate Attia's specific recommendation of ubiquinol 100–200 mg with a fat-containing meal for statin users over 60. The review comparing ubiquinol vs. ubiquinone (PMID 37971634) is most directly relevant to his preference for the reduced form, but no findings are extractable. Without accessible study content, no evidence-based comparison can be made.
"the Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo."
The Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.
None of the 10 retrieved studies directly assess the Q-SYMBIO trial or CoQ10 supplementation in heart failure patients with major adverse cardiovascular events as an endpoint. The available literature includes reviews on CoQ10 for cardiovascular disease prevention (PMID: 37971634), clinical applications of CoQ10 (PMID: 24389208), and general CoQ10 supplementation efficacy (PMID: 33325173), but none provide extractable findings (key findings are listed as 'None') that directly confirm or refute the specific 43% MACE reduction figure cited. While the Q-SYMBIO trial is a real published RCT and Rhonda Patrick's characterization of it is broadly consistent with its reported findings in the literature, the provided research corpus does not contain sufficient direct evidence to formally evaluate this claim.
"The clinical question of whether CoQ10 supplementation meaningfully reduces statin-induced myopathy has produced conflicting trial results. Some studies show benefit, others don't."
Clinical trials on whether CoQ10 supplementation meaningfully reduces statin-induced myopathy have produced conflicting results, with some studies showing benefit and others not.
None of the 10 provided studies directly address CoQ10 supplementation for statin-induced myopathy. The retrieved literature includes reviews on CoQ10 for cardiovascular disease, neurological conditions, and fertility, as well as meta-analyses focused on antioxidants and female subfertility — none of which are relevant to the specific claim about statin-induced myopathy. While the claim itself is a well-recognized area of clinical debate in the literature, the provided research does not contain the necessary trials or systematic reviews to either support or contradict it.
"The Q-SYMBIO trial in heart failure is the most compelling dataset — 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events."
The Q-SYMBIO trial, the most compelling dataset on CoQ10 and cardiovascular disease, found that 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events in heart failure patients.
None of the 10 provided research abstracts contain the Q-SYMBIO trial data or directly address CoQ10 supplementation in heart failure patients with the specific outcomes cited (cardiovascular mortality reduction, major adverse cardiac events). The available studies are largely reviews focused on fertility, neurological disease, or general CoQ10 overview, with no primary trial data from Q-SYMBIO included. While the Q-SYMBIO trial (Mortensen et al., 2014, JACC Heart Failure) is a real published RCT that does report findings broadly consistent with Attia's claim, that study is not among the provided references, so verification against the supplied evidence base is not possible.
"the Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo."
The Q-SYMBIO trial showed that CoQ10 supplementation in patients with severe heart failure reduced major adverse cardiovascular events by 43% compared to placebo.
"The clinical question of whether CoQ10 supplementation meaningfully reduces statin-induced myopathy has produced conflicting trial results. Some studies show benefit, others don't."
Clinical trials on whether CoQ10 supplementation meaningfully reduces statin-induced myopathy have produced conflicting results, with some studies showing benefit and others not.
"The Q-SYMBIO trial in heart failure is the most compelling dataset — 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events."
The Q-SYMBIO trial, the most compelling dataset on CoQ10 and cardiovascular disease, found that 420 milligrams per day of CoQ10 versus placebo over two years reduced cardiovascular death by 43% and reduced major adverse events in heart failure patients.
"The fat absorption point is important — CoQ10 is highly lipophilic and needs dietary fat for absorption."
CoQ10 is highly lipophilic and needs dietary fat for absorption, making it important to take with a fat-containing meal.
"The fat absorption point is important — CoQ10 is highly lipophilic and needs dietary fat for absorption."
CoQ10 is highly lipophilic and needs dietary fat for absorption, making it important to take with a fat-containing meal.
While Peter Attia's claim about CoQ10's lipophilicity and the need for dietary fat co-administration is pharmacologically plausible and widely cited in clinical practice, none of the 10 provided studies contain extractable key findings directly addressing this mechanistic claim. The available literature includes reviews on CoQ10 formulation challenges (PMID: 33325173) and clinical applications (PMID: 24389208) that would be expected to discuss bioavailability and absorption, but no specific findings were captured in the provided data. The claim itself is grounded in well-established pharmaceutical principles regarding lipophilic compound absorption, but the provided evidence base cannot directly confirm or refute it.
"I think part of the inconsistency comes from different CoQ10 formulations — ubiquinol versus ubiquinone — and different patient populations."
Attia believes part of the inconsistency in trial results comes from different CoQ10 formulations (ubiquinol versus ubiquinone) and different patient populations.
"Statins inhibit the same enzyme — HMG-CoA reductase — that's needed for both cholesterol synthesis and CoQ10 synthesis. Statin-induced CoQ10 depletion is thought to contribute to the muscle pain and weakness — myalgia — that affects up to 10% of statin users."
Statins inhibit HMG-CoA reductase, the same enzyme needed for both cholesterol synthesis and CoQ10 synthesis, leading to statin-induced CoQ10 depletion that is thought to contribute to muscle pain and weakness affecting up to 10% of statin users.
The provided research corpus does not contain studies directly evaluating the mechanistic claim about statin-induced HMG-CoA reductase inhibition leading to CoQ10 depletion and myopathy. While several CoQ10 reviews are listed (PMIDs 33325173, 24389208, 37971634, 34129891, 35199552, 32933108), none report key findings or population data relevant to statin-CoQ10 interactions, making direct comparison impossible. The remaining studies focus on fertility, bipolar disorder, and cardiovascular disease prevention, which are entirely unrelated to the mechanistic claim. Although the biochemical rationale Rhonda Patrick describes (shared mevalonate pathway for cholesterol and CoQ10) is well-established in pharmacology literature, the specific studies provided here cannot be used to confirm or refute either the mechanism or the 10% myopathy prevalence figure.
"Statins inhibit the same enzyme — HMG-CoA reductase — that's needed for both cholesterol synthesis and CoQ10 synthesis. Statin-induced CoQ10 depletion is thought to contribute to the muscle pain and weakness — myalgia — that affects up to 10% of statin users."
Statins inhibit HMG-CoA reductase, the same enzyme needed for both cholesterol synthesis and CoQ10 synthesis, leading to statin-induced CoQ10 depletion that is thought to contribute to muscle pain and weakness affecting up to 10% of statin users.
"I think part of the inconsistency comes from different CoQ10 formulations — ubiquinol versus ubiquinone — and different patient populations."
Attia believes part of the inconsistency in trial results comes from different CoQ10 formulations (ubiquinol versus ubiquinone) and different patient populations.
Attia's claim that formulation differences (ubiquinol vs. ubiquinone) and patient population heterogeneity contribute to inconsistent CoQ10 trial results is conceptually supported by the literature available. PMID 37971634 is a review specifically comparing ubiquinone and ubiquinol supplementation for cardiovascular outcomes, which directly addresses the formulation distinction Attia raises. PMID 33325173 also reviews CoQ10 formulation challenges, lending further credence to the idea that bioavailability and formulation differences are recognized sources of variability. However, none of the provided studies include key findings, populations, or limitations data, making it impossible to confirm whether these reviews explicitly attribute trial inconsistency to formulation type or patient population differences with empirical rigor. The support is therefore plausible and mechanistically grounded but not directly demonstrated by the evidence presented here.
"CoQ10, or ubiquinone, sits at the junction of Complex I and Complex II feeding electrons to Complex III in the mitochondrial electron transport chain."
CoQ10 (ubiquinone) sits at the junction of Complex I and Complex II, feeding electrons to Complex III in the mitochondrial electron transport chain.
The expert's claim describes a well-established biochemical mechanism: CoQ10 (ubiquinone) acts as a mobile electron carrier in the inner mitochondrial membrane, accepting electrons from both Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase) and donating them to Complex III (ubiquinol-cytochrome c reductase). This mechanistic description is consistent with foundational biochemistry and is referenced implicitly in several of the provided reviews (e.g., PMIDs 33325173, 34129891, 24389208, 35199552), which discuss CoQ10's role in the electron transport chain. However, none of the provided studies directly test or describe this specific mechanistic claim with primary data — they are all reviews or meta-analyses focused on clinical or supplementation outcomes, and their key findings are not reported here. The mechanism itself is not disputed in the literature, but direct confirmatory evidence from the listed studies cannot be cited.
"Coenzyme Q10 — CoQ10 — is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane. It serves two essential functions: it's a critical electron carrier in the mitochondrial respiratory chain between Complex I/II and Complex III, and it's one of the most important fat-soluble antioxidants in the body."
CoQ10 is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane, serving as a critical electron carrier in the mitochondrial respiratory chain and as a major fat-soluble antioxidant.
"its synthesis requires the same mevalonate pathway that statins block — which is why statin therapy reduces plasma and tissue CoQ10 levels."
CoQ10 synthesis requires the same mevalonate pathway that statins block, which is why statin therapy reduces plasma and tissue CoQ10 levels.
The provided research corpus does not contain studies that directly address the mechanistic claim about statins blocking the mevalonate pathway and thereby reducing CoQ10 synthesis. While several reviews on CoQ10 (PMIDs 33325173, 24389208, 37971634, 34129891, 35199552, 32933108) are present, none report key findings that can be directly evaluated against Attia's mechanistic claim. The claim itself is well-established biochemical knowledge in the broader literature, but the specific studies provided here do not supply extractable evidence to confirm or refute it.
"CoQ10 levels decline with age — by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults. This decline is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues."
CoQ10 levels decline with age, and by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults, which is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.
"Coenzyme Q10 — CoQ10 — is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane. It serves two essential functions: it's a critical electron carrier in the mitochondrial respiratory chain between Complex I/II and Complex III, and it's one of the most important fat-soluble antioxidants in the body."
CoQ10 is a fat-soluble compound synthesized in virtually every cell of the body and concentrated in the inner mitochondrial membrane, serving as a critical electron carrier in the mitochondrial respiratory chain and as a major fat-soluble antioxidant.
The expert's claim describes well-established biochemistry of CoQ10 — its fat-solubility, endogenous synthesis, mitochondrial localization, role as an electron carrier in the respiratory chain, and antioxidant function. Several reviews in the provided literature (PMIDs 24389208, 34129891, 33325173, 37971634) are consistent with these mechanistic descriptions as they discuss CoQ10's clinical applications, formulation, and cardiovascular relevance, which presuppose this biochemistry. However, the available studies do not directly report these mechanistic findings as key outcomes — all provided key findings fields are listed as 'None,' and the studies are largely focused on supplementation efficacy, fertility, or clinical applications rather than directly validating the underlying biochemistry. The claim is therefore supported by scientific consensus reflected in the review literature, but direct confirmatory data from the provided abstracts cannot be explicitly cited.
"The heart, which has the highest energy demands of any organ, is particularly vulnerable to CoQ10 depletion."
The heart is particularly vulnerable to CoQ10 depletion due to having the highest energy demands of any organ.
"The ubiquinol form — the reduced, active form — has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired."
The ubiquinol form of CoQ10 has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.
"CoQ10, or ubiquinone, sits at the junction of Complex I and Complex II feeding electrons to Complex III in the mitochondrial electron transport chain."
CoQ10 (ubiquinone) sits at the junction of Complex I and Complex II, feeding electrons to Complex III in the mitochondrial electron transport chain.
"It's also the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation."
CoQ10 is the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.
The expert's claim that CoQ10 is the *main* fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation is a mechanistic assertion that requires direct biochemical evidence to evaluate. None of the 10 retrieved studies provide key findings that directly address this specific mechanistic claim — all key finding fields are null. While several reviews (e.g., PMID 34129891 on Coenzyme Q, PMID 33325173 on CoQ10 supplementation, PMID 24389208 on clinical applications) could plausibly contain relevant mechanistic content, no extractable data is available to confirm or refute the claim. The broader literature does support CoQ10's antioxidant role in mitochondrial membranes, but the claim that it is the *primary* fat-soluble antioxidant in that context would need to be weighed against the role of vitamin E (alpha-tocopherol), which is also well-established as a major fat-soluble membrane antioxidant.
"CoQ10 levels decline with age — by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults. This decline is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues."
CoQ10 levels decline with age, and by age 70, tissue CoQ10 can be 50 to 70% lower than in young adults, which is thought to contribute to mitochondrial dysfunction and increased oxidative stress in aging tissues.
While the expert's claim about age-related CoQ10 decline is a widely cited concept in the CoQ10 literature, none of the 10 provided studies directly report quantitative data on the magnitude of tissue CoQ10 decline with aging (i.e., the specific 50–70% reduction figure by age 70). The available studies are reviews and meta-analyses focused on supplementation efficacy, cardiovascular outcomes, fertility, and neurological applications, none of which provide key findings or population data that directly validate or contradict the specific numerical claim. The mechanistic assertion linking CoQ10 decline to mitochondrial dysfunction and oxidative stress is biologically plausible and consistent with the general focus of these CoQ10 reviews, but direct evidence from the provided literature cannot be extracted to confirm the precise figures cited.
"its synthesis requires the same mevalonate pathway that statins block — which is why statin therapy reduces plasma and tissue CoQ10 levels."
CoQ10 synthesis requires the same mevalonate pathway that statins block, which is why statin therapy reduces plasma and tissue CoQ10 levels.
"The heart, which has the highest energy demands of any organ, is particularly vulnerable to CoQ10 depletion."
The heart is particularly vulnerable to CoQ10 depletion due to having the highest energy demands of any organ.
None of the 10 retrieved studies directly address the claim that the heart is particularly vulnerable to CoQ10 depletion due to having the highest energy demands of any organ. The available publications are predominantly reviews and meta-analyses focused on CoQ10 supplementation for cardiovascular disease prevention (PMID 37971634), clinical applications (PMID 24389208), fertility (PMIDs 39019217, 32851663, 38184959), neurological diseases (PMID 35199552), and CoQ10 metabolism disorders (PMID 32933108), none of which provide direct empirical data comparing organ-specific CoQ10 concentrations or vulnerability to depletion. While the mechanistic premise that cardiac tissue has high energy demands and contains elevated CoQ10 concentrations is a well-established concept in biochemistry, none of the listed studies explicitly test or confirm this specific claim.
"It's also the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation."
CoQ10 is the main fat-soluble antioxidant protecting mitochondrial membranes from lipid peroxidation.
"The ubiquinol form — the reduced, active form — has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired."
The ubiquinol form of CoQ10 has significantly better bioavailability than ubiquinone, particularly in older individuals whose ability to convert ubiquinone to ubiquinol may be impaired.
The available research corpus includes several reviews on CoQ10 (PMIDs 33325173, 24389208, 37971634, 34129891, 35199552) that are topically relevant, but none of the provided records include extractable key findings, population data, or limitations that directly address the comparative bioavailability of ubiquinol versus ubiquinone or the age-related conversion impairment mechanism. PMID 37971634 ('Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol)...') is the most directly relevant title, but no key findings are provided to assess its conclusions. Without accessible data from these studies, it is not possible to confirm or refute Patrick's claim with the evidence as presented.
"In my clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though I acknowledge this is clinical observation rather than a controlled trial."
In Attia's clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though he acknowledges this is clinical observation rather than a controlled trial.
The provided research corpus does not contain any studies directly evaluating CoQ10 or ubiquinol supplementation for statin-induced myalgia. While several reviews on CoQ10 clinical applications (PMIDs 24389208, 33325173, 37971634) are present in the list, no key findings, populations, or limitations were extractable from the provided abstracts, making direct comparison impossible. The remaining studies focus on unrelated topics such as bipolar disorder, female fertility, and neurological diseases, offering no relevant evidence for or against Attia's clinical observation. Because Attia himself frames this as clinical observation rather than a controlled trial, the absence of supporting RCT-level evidence in this corpus is expected but means the claim cannot be formally evaluated.
"I supplement with ubiquinol at 100 to 200 milligrams with fat-containing meals."
Rhonda Patrick personally supplements with ubiquinol at 100 to 200 milligrams taken with fat-containing meals.
The claim is a personal anecdote about Rhonda Patrick's own supplementation regimen (100–200 mg ubiquinol with fat-containing meals), which by definition cannot be directly supported or contradicted by published research. The provided studies include reviews and meta-analyses on CoQ10/ubiquinol in various contexts (cardiovascular disease, fertility, neurological conditions), but none contain key findings, populations, or limitations data as presented, making meaningful comparison impossible. While the practice of taking fat-soluble supplements like ubiquinol with fatty meals is pharmacokinetically reasonable and the dose range cited is within ranges discussed in CoQ10 literature (e.g., PMID 33325173, PMID 37971634), no study in this list directly validates or refutes this specific personal protocol.
"I supplement with ubiquinol at 100 to 200 milligrams with fat-containing meals."
Rhonda Patrick personally supplements with ubiquinol at 100 to 200 milligrams taken with fat-containing meals.
"In my clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though I acknowledge this is clinical observation rather than a controlled trial."
In Attia's clinical experience, patients on high-intensity statin therapy who report myalgia often improve with 200 to 400 milligrams of ubiquinol per day, though he acknowledges this is clinical observation rather than a controlled trial.
"While the evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, the mechanistic rationale is sound."
The evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, though the mechanistic rationale is sound.
"While the evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, the mechanistic rationale is sound."
The evidence that CoQ10 supplementation fully reverses statin myopathy is mixed, though the mechanistic rationale is sound.
None of the 10 provided studies directly address CoQ10 supplementation for statin-induced myopathy. The retrieved literature focuses on fertility, cardiovascular disease, neurological conditions, and bipolar disorder — none of which are relevant to the specific claim about statin myopathy. While two reviews (PMIDs 33325173 and 24389208) cover CoQ10 broadly, no key findings were extractable, and neither is identified as examining statin myopathy outcomes. The claim itself is cautiously framed — acknowledging mixed evidence and sound mechanistic rationale — which is a defensible scientific posture, but the provided research base cannot confirm or contradict it.
"For a supplement, that's a striking result, though heart failure patients are a specific population with low CoQ10 levels at baseline."
Attia notes the Q-SYMBIO result is striking for a supplement, but qualifies that heart failure patients are a specific population with low CoQ10 levels at baseline.
"For a supplement, that's a striking result, though heart failure patients are a specific population with low CoQ10 levels at baseline."
Attia notes the Q-SYMBIO result is striking for a supplement, but qualifies that heart failure patients are a specific population with low CoQ10 levels at baseline.
None of the 10 provided studies directly address the Q-SYMBIO trial, CoQ10 supplementation in heart failure patients, or the specific claim about baseline CoQ10 deficiency in that population. The available literature covers CoQ10 in fertility, neurological disease, cardiovascular disease prevention broadly, and metabolic disorders — but none provide extractable findings (all key findings are listed as 'None') relevant to Attia's specific claim about the Q-SYMBIO result and heart failure patient populations. Without direct evidence from the Q-SYMBIO trial or comparable heart failure-specific CoQ10 research in the provided set, no meaningful assessment can be made.
"For healthy people, the case is weaker. If your mitochondria are functioning well, additional CoQ10 may not do much."
For healthy people, the case for CoQ10 is weaker; if mitochondria are functioning well, additional CoQ10 may not do much.
"heart failure patients shouldn't change their medication without medical supervision."
Heart failure patients should not change their medication without medical supervision, even given the striking Q-SYMBIO trial result.
None of the 10 provided studies directly address the Q-SYMBIO trial, heart failure management, or the specific caution about medication changes in heart failure patients. The available literature covers CoQ10 in contexts such as cardiovascular disease prevention, fertility, neurological diseases, and bipolar disorder, but none provide direct evidence bearing on medication supervision in heart failure. While the expert's caution is clinically reasonable and consistent with standard medical practice, the provided research base cannot be used to formally support or contradict this specific claim.
"heart failure patients shouldn't change their medication without medical supervision."
Heart failure patients should not change their medication without medical supervision, even given the striking Q-SYMBIO trial result.
"For healthy people, the case is weaker. If your mitochondria are functioning well, additional CoQ10 may not do much."
For healthy people, the case for CoQ10 is weaker; if mitochondria are functioning well, additional CoQ10 may not do much.
The published research provided contains no extractable key findings, populations, or limitations for any of the 10 studies listed, making it impossible to directly evaluate Attia's claim that CoQ10 supplementation offers limited benefit in healthy individuals with well-functioning mitochondria. The studies span reviews and meta-analyses on CoQ10 in contexts such as cardiovascular disease, neurological conditions, fertility, and metabolic disorders, but none appear to specifically examine healthy populations with normal mitochondrial function as their primary focus. Without accessible data from these sources, no meaningful evidence-based comparison can be made. The claim is biologically plausible given CoQ10's role as an endogenous compound synthesized by the body, but plausibility alone does not constitute evidentiary support.
"CoQ10 is one of the supplements I think about seriously from a mitochondrial function standpoint, and it has particular clinical relevance for my patients who are on statins."
CoQ10 is a supplement Attia thinks about seriously from a mitochondrial function standpoint, with particular clinical relevance for patients on statins.
The published research provided includes relevant reviews on CoQ10 (PMIDs 33325173, 24389208, 37971634, 34129891, 35199552, 32933108), which collectively support the biological plausibility of CoQ10's role in mitochondrial function and its clinical applications. The statin-CoQ10 connection is a well-established mechanistic concern in the literature, as statins inhibit the mevalonate pathway used in CoQ10 synthesis. However, none of the provided studies contain extractable key findings, populations, or limitations data, preventing direct evidentiary confirmation of Attia's specific clinical claims. The claim is labeled as a 'passing mention,' which lowers the evidentiary bar, but the absence of detailed study data limits a definitive assessment.
"CoQ10 is one of the supplements I think about seriously from a mitochondrial function standpoint, and it has particular clinical relevance for my patients who are on statins."
CoQ10 is a supplement Attia thinks about seriously from a mitochondrial function standpoint, with particular clinical relevance for patients on statins.